Literature DB >> 19008330

Corticotropin-releasing hormone receptor expression and functional signaling in murine gonadotrope-like cells.

Audrey F Seasholtz1, Miina Ohman, Amale Wardani, Robert C Thompson.   

Abstract

Corticotropin-releasing hormone (CRH) is a key regulator of the mammalian stress response, mediating a wide variety of stress-associated behaviors including stress-induced inhibition of reproductive function. To investigate the potential direct action of CRH on pituitary gonadotrope function, we examined CRH receptor expression and second messenger signaling in alpha T3-1 cells, a murine gonadotrope-like cell line. Reverse transcriptase PCR (RT-PCR) studies demonstrated that alpha T3-1 cells express mRNA for the two CRH receptor subtypes, CRHR1 and CRHR2, with CRHR2alpha as the predominant CRHR2 isoform. Stimulation of the cells with CRH or urocortin (UCN) resulted in rapid, transient increases in the intracellular levels of cAMP that were completely blocked by the addition of alpha-helical CRH 9-41 or astressin, non-selective CRH receptor antagonists. Stimulation of the cells with CRHR2-specific ligands, urocortin 2 (UCN2) or urocortin 3 (UCN3), resulted in rapid increases in intracellular cAMP levels to 50-60% of the levels observed with UCN. Treatment with a selective CRHR2 antagonist, antisauvagine, completely blocked UCN3-mediated increases in cAMP and significantly reduced, but did not completely block UCN-mediated increases in cAMP, demonstrating that both CRHR1 and CRHR2 are functionally active in these gonadotrope-like cells. Finally, UCN treatment significantly increased the transcriptional activity of the glycoprotein hormone alpha-subunit promoter as assessed by alpha-luciferase transfection assays. Together, these results demonstrate the functional signaling of CRH receptors in alpha T3-1 cells, suggesting that CRH may also modulate pituitary gonadotrope function in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19008330      PMCID: PMC2635417          DOI: 10.1677/JOE-08-0139

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  53 in total

1.  Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity.

Authors:  Olaf Brauns; Simone Brauns; Marc Jenke; Bodo Zimmermann; Frank M Dautzenberg
Journal:  Peptides       Date:  2002-10       Impact factor: 3.750

Review 2.  CRH-BP: the regulation and function of a phylogenetically conserved binding protein.

Authors:  Nicole J Westphal; Audrey F Seasholtz
Journal:  Front Biosci       Date:  2006-05-01

3.  Transcriptional regulation of the glycoprotein hormone alpha-subunit gene by pituitary adenylate cyclase-activating polypeptide (PACAP) in alphaT3-1 cells.

Authors:  B Attardi; S J Winters
Journal:  Mol Cell Endocrinol       Date:  1998-02       Impact factor: 4.102

4.  Cell-specific expression of the mouse glycoprotein hormone alpha-subunit gene requires multiple interacting DNA elements in transgenic mice and cultured cells.

Authors:  M L Brinkmeier; D F Gordon; J M Dowding; T L Saunders; S K Kendall; V D Sarapura; W M Wood; E C Ridgway; S A Camper
Journal:  Mol Endocrinol       Date:  1998-05

5.  Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor.

Authors:  K Lewis; C Li; M H Perrin; A Blount; K Kunitake; C Donaldson; J Vaughan; T M Reyes; J Gulyas; W Fischer; L Bilezikjian; J Rivier; P E Sawchenko; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

6.  Involvement of the corticotropin-releasing factor (CRF) type 2 receptor in CRF-induced thyrotropin release by the amphibian pituitary gland.

Authors:  Reiko Okada; Mark F Miller; Kazutoshi Yamamoto; Bert De Groef; Robert J Denver; Sakaé Kikuyama
Journal:  Gen Comp Endocrinol       Date:  2006-12-26       Impact factor: 2.822

7.  Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors.

Authors:  T M Reyes; K Lewis; M H Perrin; K S Kunitake; J Vaughan; C A Arias; J B Hogenesch; J Gulyas; J Rivier; W W Vale; P E Sawchenko
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

8.  Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary.

Authors:  E Potter; S Sutton; C Donaldson; R Chen; M Perrin; K Lewis; P E Sawchenko; W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

Review 9.  The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology.

Authors:  Edward W Hillhouse; Dimitris K Grammatopoulos
Journal:  Endocr Rev       Date:  2006-02-16       Impact factor: 19.871

10.  Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.

Authors:  Olaf Jahn; Hossein Tezval; Lars van Werven; Klaus Eckart; Joachim Spiess
Journal:  Neuropharmacology       Date:  2004-08       Impact factor: 5.250

View more
  3 in total

1.  Soluble corticotropin-releasing hormone receptor 2alpha splice variant is efficiently translated but not trafficked for secretion.

Authors:  Ryan T Evans; Audrey F Seasholtz
Journal:  Endocrinology       Date:  2009-06-11       Impact factor: 4.736

2.  Deep sequencing of the transcriptome in the anterior pituitary of heifers before and after ovulation.

Authors:  Kiran Pandey; Yoichi Mizukami; Kenji Watanabe; Syuiti Sakaguti; Hiroya Kadokawa
Journal:  J Vet Med Sci       Date:  2017-04-23       Impact factor: 1.267

3.  Deciphering the Contributions of CRH Receptors in the Brain and Pituitary to Stress-Induced Inhibition of the Reproductive Axis.

Authors:  Androniki Raftogianni; Lena C Roth; Diego García-González; Thorsten Bus; Claudia Kühne; Hannah Monyer; Daniel J Spergel; Jan M Deussing; Valery Grinevich
Journal:  Front Mol Neurosci       Date:  2018-08-30       Impact factor: 5.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.